Search

Your search keyword '"Filshie, Robin J. A."' showing total 14 results
Start Over Author "Filshie, Robin J. A."
14 results on '"Filshie, Robin J. A."'

2. Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy

Author

Maierhofer, Anna, primary, Fox, Lucy C, additional, Hutter, Stephan, additional, Baer, Constance, additional, Thompson, Ella, additional, Nguyen, Tamia, additional, Den Elzen, Nicole, additional, Filshie, Robin J, additional, Tiong, Ing S, additional, Nadarajah, Niroshan, additional, Meggendorfer, Manja, additional, Kern, Wolfgang, additional, Haferlach, Claudia, additional, Haferlach, Torsten, additional, and Blombery, Piers, additional

Published
2022
Full Text
View/download PDF

3. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Author

Yeung, David T, primary, Shanmuganathan, Naranie, additional, Reynolds, John, additional, Branford, Susan, additional, Walia, Mannu, additional, Yong, Agnes S.M., additional, Shortt, Jake, additional, Burbury, Kate, additional, Viiala, Nicholas, additional, Cunningham, Ilona, additional, Ross, David M., additional, Harrup, Rosemary, additional, Wright, Matthew, additional, Forsyth, Cecily, additional, D'Souza, Alwyn Bernard, additional, Filshie, Robin J, additional, Browett, Peter J., additional, Lane, Steven W, additional, Grove, Carolyn, additional, Grigg, Andrew, additional, and Hughes, Timothy, additional

Published
2022
Full Text
View/download PDF

4. Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia - the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Author

McQuilten, Zoe, primary, Fox, Lucy C, additional, Fox, Vanessa, additional, Heritier, Stephane, additional, Batt, Tracey J, additional, Blombery, Piers, additional, Curnow, Jennifer, additional, Higgins, Alisa, additional, Hiwase, Devendra, additional, Filshie, Robin J, additional, Firkin, Frank, additional, Lacaze, Paul, additional, Mason, Kylie D, additional, Mills, Tony, additional, Patil, Sushrut S., additional, Pepperell, Dominic, additional, Stevenson, William S, additional, Szer, Jeffrey, additional, Waters, Neil, additional, Wilson, Kate, additional, Ting, Stephen B, additional, and Wood, Erica M., additional

Published
2022
Full Text
View/download PDF

6. Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Author

Zeidan, Amer M., primary, Borate, Uma, additional, Pollyea, Daniel A., additional, Brunner, Andrew M., additional, Roncolato, Fernando, additional, Garcia, Jacqueline S., additional, Filshie, Robin J, additional, Odenike, Olatoyosi, additional, Watson, Anne-Marie, additional, Krishnadasan, Ravi, additional, Bajel, Ashish, additional, Naqvi, Kiran, additional, Zha, Jiuhong, additional, Hogdal, Leah, additional, Zhou, Ying, additional, Hoffman, David, additional, Kye, Steve, additional, and Garcia-Manero, Guillermo, additional

Published
2021
Full Text
View/download PDF

7. Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Author

Verner, Emma, primary, Johnston, Amanda, additional, Pati, Nalini, additional, Hawkes, Eliza, additional, Lee, Hui-Peng, additional, Cochrane, Tara, additional, Cheah, Chan-Yoon, additional, Filshie, Robin J, additional, Purtill, Duncan, additional, Sia, Hanlon, additional, Enjeti, Anoop Kumar, additional, Brown, Christina, additional, Murphy, Nicholas E., additional, Curnow, Jennifer, additional, Lee, Kenneth, additional, Walia, Mannu, additional, Butcher, Belinda, additional, and Trotman, Judith, additional

Published
2021
Full Text
View/download PDF

8. Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Author

McCaughan, Georgia J, primary, Tran, Steven, additional, Durrant, Simon, additional, Harrison, Simon J, additional, Morton, James, additional, Horvath, Noemi, additional, Spencer, Andrew, additional, Kerridge, Ian H., additional, Er, Jeremy An Ke, additional, Barge, Luani, additional, Bryant, Adam, additional, Filshie, Robin J, additional, Choong, Emily, additional, Lai, Hock Choong, additional, Tiley, Campbell, additional, Mills, Anthony K, additional, Butler, Andrew, additional, Moore, John, additional, Hertzberg, Mark, additional, Kennedy, Glen A, additional, Ho, P. Joy, additional, Sidiqi, M Hasib, additional, Bashford, John, additional, Routledge, David, additional, Taylor, Kerry, additional, Lee, Cindy H., additional, Kalff, Anna, additional, Xia, Wei, additional, and Hamad, Nada, additional

Published
2020
Full Text
View/download PDF

12. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Author

Ross, David M., Pagani, Ilaria S., Shanmuganathan, Naranie, Kok, Chung H., Seymour, John F., Mills, Anthony K., Filshie, Robin J., Arthur, Christopher K., Dang, Phuong, Saunders, Verity A., Braley, Jodi, Yong, Agnes S., Yeung, David T., White, Deborah L., Grigg, Andrew P., Schwarer, Anthony P., Branford, Susan, and Hughes, Timothy P.

Abstract

Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLG CML8 study enrolled 40 imatinib-treated patients with undetectable BCR-ABL1mRNA (approximately MR4.5). Molecular relapse was defined as detectable BCR-ABL1on two consecutive tests or any single value >0.1%. With a median follow-up of 8.6 years (range 5.7–11.2 years), 18 patients remain in continuous TFR (45.0%; 95% confidence interval 31.9−63.4%). The latest relapse detected was 27 months after stopping imatinib. No patient progressed to advanced phase. Twenty-two patients met criteria for imatinib re-treatment and all regained undetectable molecular response. Nine patients in long-term TFR were monitored by highly sensitive individualized BCR-ABL1DNA PCR in a sufficient number of samples to enable more precise quantification of residual leukemia. BCR-ABL1DNA decreased from a median of MR5.0in the first year of TFR to MR6.1in the sixth year of TFR. Our results support the long-term safety and remarkable stability of response after imatinib discontinuation in appropriately selected CML patients. Serial high sensitivity testing provides a new and unexpected finding of gradually reducing CML cells in patients in long-term TFR.

Published
2018
Full Text
View/download PDF

14. Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation.

Author

Filshie RJ

Subjects
Animals, Clinical Trials as Topic, Cytokines pharmacology, Granulocyte Colony-Stimulating Factor therapeutic use, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Humans, Receptors, Growth Factor agonists, Stem Cell Factor therapeutic use, Thrombopoietin therapeutic use, Cytokines therapeutic use, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation
Abstract

Haemopoietic progenitors mobilised into peripheral blood are now almost universally used in autologous haemopoietic stem cell transplantation in the treatment of a range of malignant and some nonmalignant disease. Although chemotherapy alone was initially used, all modern protocols now involve the use of cytokines, with or without chemotherapy. Important developments have included an in understanding of the importance of prior cancer therapy on progenitor yield, knowledge of the kinetics of mobilisation and development of necessary skills to collect and cryopreserve progenitors. More accurate measurement of haemopoietic progenitors and definitions of target cell yields for optimal haemopoietic recovery after high-dose therapy have also contributed to more predictable outcomes and provide a reference point for newer mobilisation approaches. Although G-CSF based regimens are usually successful, some patients either fail to mobilise sufficient progenitors or require an excessive number of collections. Clinical studies with the early acting cytokine, stem cell factor, in combination with G-CSF have demonstrated increased progenitor yields in a range of patients which may translate to clinical benefit in selected situations. In animal models and to a lesser extent in humans, other cytokines such as thrombopoietin and Flt-3 ligand or a number of engineered small molecules with single or dual agonist activity for cytokine receptors (IL-3, Flt-3L, TPO, G-CSF), have also been found to be promising mobilising agents. Further research into the relative importance of cell proliferation, cellular adhesion and the role of accessory cells and other signalling events is leading to an improved understanding of the underlying mechanisms of haemopoietic progenitor mobilisation. Administration of appropriate high-dose chemotherapy followed by re-infusion of haemopoietic progenitor cells capable of long-term reconstitution has long had a place in the treatment of a number of malignant (largely haematological) and non-malignant diseases. For many years these progenitor cells were obtained by direct aspiration of bone marrow under general anaesthetic, hence the term bone marrow transplantation. However, it has also been recognized that haemopoietic stem cells may be recovered from peripheral blood, albeit in low numbers, and also from umbilical cord blood. Further empirical observations showed that the number of haemopoietic progenitors circulating in the blood could be transiently augmented after chemotherapy and/or administration of one or more of a number of cytokines. Refinements to the clinical practice of progenitor mobilisation, collection and enumeration have proved very successful such that in many cases peripheral blood stem cells (PBSC) have largely replaced bone marrow as the preferred source.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results